支持方:是否应停止IgA肾病免疫抑制治疗?
KDIGO指南建议对持续蛋白尿≥1 g/天且GFR>50 mL/min/1.73 m²的IgA肾病患者使用6个月糖皮质激素。STOP-IgAN研究将177例蛋白尿>0.75 g/天的患者随机分为继续支持治疗或支持治疗联合免疫抑制,观察36个月后认为联合免疫抑制无获益。本文从时间平均蛋白尿、支持治疗未能降低蛋白尿至1 g/天以下以及缺乏组织学评估三方面对该结论提出质疑,认为需要更长随访评估。
要点
- KDIGO指南建议对持续蛋白尿≥1 g/天且GFR>50 mL/min/1.73 m²的IgA肾病患者使用6个月糖皮质激素。
- STOP-IgAN研究36个月观察显示,在综合支持治疗基础上加用免疫抑制对中度蛋白尿且CKD 1-3期IgA肾病患者无获益。
- 作者认为该研究结论存疑:时间平均蛋白尿的获益需更长观察期显现,支持治疗未能降低蛋白尿至1 g/天以下,且缺乏组织学评估。
核心结论
- 作者认为STOP-IgAN研究关于免疫抑制无获益的结论值得商榷,需要更长随访期进一步评估以获得更可靠的答案。
研究设计与样本
- STOP-IgAN研究纳入德国32个肾脏病中心的379例IgA肾病患者,经过6个月支持治疗导入期后,177例蛋白尿>0.75 g/天的患者随机接受继续支持治疗或支持治疗联合免疫抑制(糖皮质激素单药或三种免疫抑制剂联合治疗),观察36个月。
主要发现
- STOP-IgAN研究报道,经过36个月观察,在持续综合支持治疗基础上加用免疫抑制剂对中度蛋白尿且慢性肾脏病1-3期的IgA肾病患者无获益。
- 支持治疗组在36个月观察期间估算GFR年下降1.6 mL/min/1.73 m²,但未能将蛋白尿降至1 g/天以下;而6个月激素治疗可将蛋白尿降至1 g/天以下。
- 作者指出,关于时间平均蛋白尿的研究显示,对肾脏存活的获益在36个月时未显现,但在更长观察期内出现。
- 作者指出,STOP-IgAN研究缺乏任何组织学数据评估,无法监测形态学病变对肾脏存活和治疗效果的重要性。
关键数值与推荐
- KDIGO指南建议,对经3-6个月RAS阻断剂治疗后仍持续蛋白尿≥1 g/天且GFR>50 mL/min/1.73 m²的IgA肾病患者,使用6个月疗程的糖皮质激素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出STOP-IgAN研究的结论存在以下问题:时间平均蛋白尿的获益在36个月时未显现,需更长观察期;支持治疗未能降低蛋白尿至1 g/天以下;缺乏组织学数据评估。
- 作者认为需要更长随访期进一步评估,以获得比该研究弱证据更可靠的答案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest a 6-month course of corticosteroids (CS) for IgA nephropathy (IgAN) patients with persistent proteinuria ≥1 g/day despite 3-6 months of renin-angiotensin system (RAS) blockers and glomerular filtration rate (GFR) >50 mL/min/1.73 m2 In December 2015, Rauen et al. (N Engl J Med 2015; 373: 2225-2236) published an article entitled 'Intensive supportive care plus immunosuppression in IgA nephropathy' (STOP-IgAN), which presented results from 379 IgAN patients from 32 nephrology centres in Germany. During a run-in phase of 6 months, patients received supportive care therapy including RAS blockers, dietary counselling, advice to stop smoking and avoid nephrotoxic drugs, and statins if required. After 6 months, 177 patients with proteinuria >0.75 g/day (non-responder patients) were randomized to either receive continued supportive care or supportive care plus immunosuppression (monotherapy with CS or combined therapy with three immunosuppressants). The authors reported that, after 36 months of observation, the addition of immunosuppressants to ongoing comprehensive supportive care was not beneficial in IgAN patients with moderate proteinuria and chronic kidney disease stages 1-3. These conclusions are questionable for several reasons: (i) studies on time-average proteinuria have shown that beneficial effects on renal survival, not evident after 36 months, emerge over the course of longer observation periods; (ii) supportive care in the STOP-IgAN study resulted in a small loss of renal function during the 36 months of observation (annual decrease in the estimated GFR of 1.6 mL/min/1.73 m2), but was unable to reduce proteinuria below 1 g/day; in contrast, 6 months of steroid therapy lowered proteinuria below 1 g/day; and (iii) the lack of any assessment of the histological data does not allow the importance of the morphological lesions on renal survival and therapy effects to be monitored. Further evaluation with a longer follow-up period is needed to obtain more reliable answers than the weak evidence of this study.
引用
- Pozzi C. Pro: STOP immunosuppression in IgA nephropathy? Nephrol Dial Transplant. 2016. PMID: 27515694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。